Guideline recommends Olympus technology, 11/16

November 2016—Olympus announced that the American Urological Association, together with the Society of Urologic Oncology, included the Olympus Narrow Band Imaging (NBI) technology in its newly released guideline for the diagnosis and treatment of non-muscle invasive bladder cancer.

The AUA/SUO provides, in the evidence-based guideline, recommendations on actions that should or should not be taken based on risks and benefits.

NBI is a patented endoscopic light technology that aims to enable effective targeting of biopsies not seen under white light, without the use of dyes or drugs. White light uses all colors in the spectrum while NBI uses only blue and green, which are strongly absorbed by blood and appear darker than normal tissue. The technology enhances visibility of vascular structures on the mucosal surface. NBI is not intended to replace histopathological sampling as a means of diagnosis.

Olympus, 484-896-5000